Event Announcement: Harmony Biosciences Holdings, Inc. will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on September 4, 2025, at 2:10 p.m. ET.
Webcast Availability: A webcast of the fireside chat will be accessible on the investor page of the Harmony Biosciences website.
Company Overview: Harmony Biosciences is focused on developing therapies for rare neurological diseases and aims to address unmet medical needs through innovative science.
Foundation and Vision: Established in 2017 by Paragon Biosciences, the company emphasizes empathy and innovation to create therapeutic possibilities and foster community programs.
HRMY
$39.17+Infinity%1D
Analyst Views on HRMY
Wall Street analysts forecast HRMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRMY is 46.00 USD with a low forecast of 32.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast HRMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRMY is 46.00 USD with a low forecast of 32.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
1 Sell
Strong Buy
Current: 38.920
Low
32.00
Averages
46.00
High
62.00
Current: 38.920
Low
32.00
Averages
46.00
High
62.00
Mizuho
Graig Suvannavejh
Outperform
maintain
$36 -> $39
2025-11-06
Reason
Mizuho
Graig Suvannavejh
Price Target
$36 -> $39
2025-11-06
maintain
Outperform
Reason
Mizuho analyst Graig Suvannavejh raised the firm's price target on Harmony Biosciences to $39 from $36 and keeps an Outperform rating on the shares following the Q3 report. The firm cites the strong Wakix performance for the target increase.
BofA
Underperform
maintain
$31 -> $32
2025-11-04
Reason
BofA
Price Target
$31 -> $32
2025-11-04
maintain
Underperform
Reason
BofA raised the firm's price target on Harmony Biosciences to $32 from $31 and keeps an Underperform rating on the shares after the company reported Q3 results after having pre-announced last week. The firm notes that its revised sales forecast reflects a slightly higher near-term launch ramp and FY25 mid-point guidance increase of 2%, adding that it raised Wakix forecasts 2%-3% in 2025-27.
Mizuho
NULL -> Outperform
maintain
$35 -> $36
2025-10-29
Reason
Mizuho
Price Target
$35 -> $36
2025-10-29
maintain
NULL -> Outperform
Reason
Mizuho raised the firm's price target on Harmony Biosciences to $36 from $35 and keeps an Outperform rating on the shares.
UBS
Buy
downgrade
$50 -> $43
2025-10-15
Reason
UBS
Price Target
$50 -> $43
2025-10-15
downgrade
Buy
Reason
UBS lowered the firm's price target on Harmony Biosciences to $43 from $50 and keeps a Buy rating on the shares. Investor concerns over Harmony Biosciences have intensified following Zygel's Phase 3 failure and the IH approval setback, while upcoming orexin agonists threaten Wakix's market position, the analyst says.
About HRMY
Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
